DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED WITH CHRONIC INFLAMMATION
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED WITH CHRONIC INFLAMMATION explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED WITH CHRONIC INFLAMMATION trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED WITH CHRONIC INFLAMMATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immune attack on tough cancers: can a combo drug beat the odds?
Disease control OngoingThis study is testing whether adding a new immunotherapy drug (varlilumab) to an existing one (nivolumab) works better than nivolumab alone for patients with aggressive B-cell lymphomas that have come back or stopped responding to standard treatments. The goal is to see if the tw…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED WITH CHRONIC INFLAMMATION
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New pill aims to boost cancer fight for seniors
Disease control TerminatedThis study is for people aged 75 and older who have just been diagnosed with certain aggressive types of lymphoma. It compares the current standard treatment (a combination of drugs called R-miniCHOP) to that same treatment plus a new oral drug called CC-486. The main goals are t…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED WITH CHRONIC INFLAMMATION
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC